The results showed that BC patients with a high expression of PDCD1, CTLA4, TIGIT, and BTLA had a better clinical prognosis, while the expression of PRLR was negatively correlated with the expression of these immune checkpoints, indicating that PRLR might participate in the immune process of BC by inhibiting the expression of the above immune checkpoints, and targeting PRLR might improve the efficacy of BC immunotherapy. This evidence concerns the gene TIGIT and breast cancer.